Time-Restricted Ketogenic Diet in Huntington's Disease: A Case Study.
Huntington's disease
energy metabolism
fasting
ketogenic diet
metabolic strategy
mitochondria dysfunction
neurodegeneration
Journal
Frontiers in behavioral neuroscience
ISSN: 1662-5153
Titre abrégé: Front Behav Neurosci
Pays: Switzerland
ID NLM: 101477952
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
04
2022
accepted:
21
06
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
Huntington's disease (HD) is a progressive, fatal neurodegenerative disorder with limited treatment options. Substantial evidence implicates mitochondria dysfunction in brain and skeletal muscle in the pathogenesis of HD. Metabolic strategies, such as fasting and ketogenic diets, theoretically enhance brain and muscle metabolism and mitochondria function, which may improve the clinical symptoms of HD. We report the case of a 41-year-old man with progressive, deteriorating HD who pursued a time-restricted ketogenic diet (TRKD) for 48 weeks. Improvements were measured in his motor symptoms (52% improvement from baseline), activities of daily living (28% improvement), composite Unified HD Rating Scale (cUHDRS) score (20% improvement), HD-related behavior problems (apathy, disorientation, anger, and irritability improved by 50-100%), and mood-related quality of life (25% improvement). Cognition did not improve. Weight remained stable and there were no significant adverse effects. This case study is unique in that a patient with progressive, deteriorating HD was managed with a TRKD, with subsequent improvements in his motor symptoms, activities of daily living, cUHDRS score, most major HD-related behavior problems, and quality of life. Our patient remains dedicated to his TRKD, which continues to provide benefit for him and his family.
Identifiants
pubmed: 35967897
doi: 10.3389/fnbeh.2022.931636
pmc: PMC9372583
doi:
Types de publication
Case Reports
Langues
eng
Pagination
931636Informations de copyright
Copyright © 2022 Phillips, McManus, Brinkhuis and Romero-Ferrando.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nutr Rev. 2003 Oct;61(10):327-41
pubmed: 14604265
Proc Natl Acad Sci U S A. 1988 Aug;85(15):5733-7
pubmed: 2456581
Science. 2018 Nov 16;362(6416):764-770
pubmed: 30442800
IUBMB Life. 2001 Apr;51(4):241-7
pubmed: 11569918
Neuropsychiatry Neuropsychol Behav Neurol. 2001 Oct-Dec;14(4):219-26
pubmed: 11725215
Arch Neurol. 1992 Nov;49(11):1161-7
pubmed: 1444883
Mov Disord. 2009 Mar 15;24(4):574-8
pubmed: 19097181
Cell. 2006 Oct 6;127(1):59-69
pubmed: 17018277
Neurology. 2017 Dec 12;89(24):2495-2502
pubmed: 29142089
Aging Dis. 2022 Jun 1;13(3):655-672
pubmed: 35656107
J Chem Neuroanat. 2004 Jun;27(3):143-64
pubmed: 15183201
Drugs. 2017 Jan;77(1):29-46
pubmed: 27988871
Hum Mol Genet. 2009 Aug 15;18(16):3048-65
pubmed: 19460884
Hum Mol Genet. 2010 Oct 15;19(20):3919-35
pubmed: 20660112
Mov Disord. 2011 Jan;26(1):130-7
pubmed: 20931633
J Neurochem. 2010 Jul;114(1):1-12
pubmed: 20403078
Eur J Neurol. 2018 Jan;25(1):24-34
pubmed: 28817209
Lancet Neurol. 2013 Jul;12(7):637-49
pubmed: 23664844
Mov Disord. 1993 Apr;8(2):183-90
pubmed: 8474487
Mov Disord. 1996 Mar;11(2):136-42
pubmed: 8684382
Front Neurosci. 2020 Feb 06;14:82
pubmed: 32116525
J Nutr Metab. 2018 Feb 11;2018:5157645
pubmed: 29607218
Lancet Neurol. 2011 Jan;10(1):83-98
pubmed: 21163446
Value Health. 2019 Jun;22(6):712-720
pubmed: 31198189
N Engl J Med. 2019 Dec 26;381(26):2541-2551
pubmed: 31881139
Epilepsy Behav. 2016 May;58:61-8
pubmed: 27060389
Nat Aging. 2021 Jan;1(1):47-59
pubmed: 35310455
Ann Neurol. 1997 May;41(5):646-53
pubmed: 9153527
Ann Neurol. 1996 Mar;39(3):385-9
pubmed: 8602759
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2911-6
pubmed: 12589027
J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):371-8
pubmed: 23833269
Brain. 1996 Dec;119 ( Pt 6):2085-95
pubmed: 9010012
Curr Opin Endocrinol Diabetes Obes. 2020 Oct;27(5):301-307
pubmed: 32773574
Physiol Behav. 2011 Jul 6;103(5):501-7
pubmed: 21501628
Neurology. 2006 Feb 14;66(3):366-72
pubmed: 16476934